by Adam | Jun 8, 2020 | News
PROVIDENCE, RI, June 8, 2020 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) a Rhode Island-based company and recognized leader in the field in the field of immunogenicity assessment today announced it has licensed its advanced in silico toolkit for biologics...
by Sarah Moniz | Dec 27, 2019 | News
Providence, R.I., December 23, 2019 – EpiVax (“EpiVax, Inc.”) continues its record-breaking performance and growth in personnel in 2019 while identifying new milestones to aspire to in 2020. The Business Development team closed 15% more contracts over 2018 and...
by Adam | Oct 23, 2019 | News
Announced today, Chugai Pharmaceutical Co., Ltd. (“Chugai”), a member of the Roche Group, will extend the company’s licensed access to the Immunogenicity Screening and Protein Reengineering Interface (ISPRI) toolkit developed by EpiVax, Inc....
by Sarah Moniz | Jun 11, 2018 | News
PROVIDENCE, R.I., June 11, 2018 — EpiVax announces their move to a new headquarters at 188 Valley Street, in the “Rising Sun” complex, a former wool mill in the Olneyville section of Providence, Rhode Island. The privately held bioinformatics company is also...
